Effect | Decrease |
Trial Design | Double blind |
Trial Length | 6+ Months |
Number of Subjects | 261 |
Gender | Both Genders |
Age Range | 65+ |
Body Types | Average, Underweight |
Supplementation of Alpha-GPC at 400mg thrice daily (1,200mg daily) for 180 days in persons with mild to moderate Alzheimer's disease was able to improve symptoms as assessed by a multitude of rating scales including ADAS, MMSE, CDI, and GDS.